Catalyst
Slingshot members are tracking this event:
Roche (RHHBY) Announces Phase 3 OAK Data Evaluating TECENTRIQ Versus Chemotherapy in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| RHHBY |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 10, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Breakthrough Therapy, Tecentriq, Metastatic Non-small Cell, Lung Cancer, Nsclc, Chemotherapy, European Society For Medical Oncology
